|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
www.natap.org
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B.
"JNJ-379 binds to the HBV core protein and has a dual mode of action
- Firstly, JNJ-379 interferes with the HBV capsid assembly, resulting in the formation of non-functional capsids devoid of HBV RNA and DNA2
- Secondly, JNJ-379 prevents cccDNA formation during de novo infection, probably by interfering with capsid disassembly."
from Jules: this report came from Arrowhead recently HBV-New Approach May be Needed: Cure Not Likely - (10/16/17)
BUT….
"Totally disagree with Arrowhead. If anything the accumulating data have become more convincing that higher cure rates are possible. I do not believe in the siRNA approach or dependence on the reactivation of the immune system to cure patients. … [believe in] antiviral s, and believe in directly targeting the virus, in this case cccDNA. Inability to decrease cccDNA levels is why we currently have low cure rates. … .. Cure in woodchucks correlated with elimination of cccDNA and drop in HBsAg…… by adding a CpAM inhibitor to Nucs, we [expect to] effectively block replication and cccDNA replenishment, allowing existing cccDNA pools to decay away in the subsequent months. Decreasing cccDNA pools (source of the problem) will also result in decreases in pgRNA and HBsAg. The HBsAg produced from integrated viral DNA is of no true clinical relevance and those hepatocytes that harbor integrated viral DNA (non-infectious) will also turn over with time and disappear as we prevent any new infections or subsequent integration events. POC for this approach will be shown…..” unnamed source
|
|
发表于 2017-10-25 10:04
